Werewolf Therapeutics, Inc.
HOWL
$1.62
-$0.07-4.14%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 1.14M | 1.89M | 3.39M | 9.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 1.14M | 1.89M | 3.39M | 9.28M |
| Cost of Revenue | 38.20M | 38.74M | 38.44M | 32.84M | 31.15M |
| Gross Profit | -38.20M | -37.60M | -36.56M | -29.45M | -21.87M |
| SG&A Expenses | 23.41M | 23.84M | 24.05M | 23.77M | 23.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.01M | 75.57M | 75.48M | 69.59M | 67.62M |
| Operating Income | -73.01M | -74.42M | -73.59M | -66.21M | -58.34M |
| Income Before Tax | -73.14M | -72.41M | -70.52M | -62.12M | -53.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.14 | -72.41 | -70.52 | -62.12 | -53.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.14M | -72.41M | -70.52M | -62.12M | -53.73M |
| EBIT | -73.01M | -74.42M | -73.59M | -66.21M | -58.34M |
| EBITDA | -71.28M | -72.65M | -71.78M | -64.38M | -56.51M |
| EPS Basic | -1.64 | -1.64 | -1.63 | -1.50 | -1.35 |
| Normalized Basic EPS | -1.03 | -1.02 | -1.01 | -0.93 | -0.83 |
| EPS Diluted | -1.64 | -1.67 | -1.65 | -1.52 | -1.38 |
| Normalized Diluted EPS | -1.03 | -1.01 | -1.01 | -0.92 | -0.83 |
| Average Basic Shares Outstanding | 177.99M | 176.53M | 173.31M | 165.40M | 157.35M |
| Average Diluted Shares Outstanding | 177.99M | 177.05M | 173.83M | 165.93M | 157.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |